Cargando…

Dimethyl fumarate-associated lymphopenia: Risk factors and clinical significance

BACKGROUND: Dimethyl fumarate (DMF), a disease-modifying therapy for multiple sclerosis (MS), causes lymphopenia in a fraction of patients. The clinical significance of this is unknown. Several cases of progressive multifocal leukoencephalopathy in lymphopenic fumarate-treated patients have raised c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Longbrake, Erin E, Naismith, Robert T, Parks, Becky J, Wu, Gregory F, Cross, Anne H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2015
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4636217/ https://www.ncbi.nlm.nih.gov/pubmed/26550483 http://dx.doi.org/10.1177/2055217315596994

Ejemplares similares

Immunological Predictors of Dimethyl Fumarate‐Induced Lymphopenia
por: Diebold, Martin, et al.
Publicado: (2022)

Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimod
Publicado: (2018)

Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimod
por: Nakhaei-Nejad, Maryam, et al.
Publicado: (2017)

Gut microbiota composition as a candidate risk factor for dimethyl fumarate-induced lymphopenia in multiple sclerosis
por: Diebold, Martin, et al.
Publicado: (2022)

Dimethyl fumarate–induced lymphopenia in MS due to differential T-cell subset apoptosis
por: Ghadiri, Mahtab, et al.
Publicado: (2017)

Genetic Study of Severe Prolonged Lymphopenia in Multiple Sclerosis Patients Treated With Dimethyl Fumarate
por: Sangurdekar, Dipen, et al.
Publicado: (2019)

Dimethyl fumarate treatment shifts the immune environment toward an anti-inflammatory cell profile while maintaining protective humoral immunity
por: Longbrake, Erin E, et al.
Publicado: (2020)

CMV meningitis associated with dimethyl fumarate therapy-induced lymphopenia in a multiple sclerosis patient
por: Kogel, Ann-Kathrin, et al.
Publicado: (2021)

Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosis
por: Lucchini, Matteo, et al.
Publicado: (2021)

Time course of lymphocyte repopulation after dimethyl fumarate-induced grade 3 lymphopenia: contribution of patient age
por: Briner, Myriam, et al.
Publicado: (2019)

Fumaric acid ester‐induced T‐cell lymphopenia in the real‐life treatment of psoriasis
por: Dickel, H., et al.
Publicado: (2019)

Application of pharmacogenomics to investigate adverse drug reactions to the disease-modifying treatments for multiple sclerosis: a case–control study protocol for dimethyl fumarate-induced lymphopenia
por: Kowalec, Kaarina, et al.
Publicado: (2017)

Dimethyl fumarate for ischemic stroke
por: Kunze, Reiner
Publicado: (2017)

Effects of dimethyl fumarate on neuroprotection and immunomodulation
por: Albrecht, Philipp, et al.
Publicado: (2012)

Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 years’ follow-up of DEFINE, CONFIRM, and ENDORSE
por: Gold, Ralf, et al.
Publicado: (2020)

Dimethyl Fumarate and Monomethyl Fumarate Promote Post-Ischemic Recovery in Mice
por: Yao, Yang, et al.
Publicado: (2016)

Effect of dimethyl fumarate on lymphocytes in RRMS: Implications for clinical practice
por: Mehta, Devangi, et al.
Publicado: (2019)

Dimethyl fumarate mitigates optic neuritis
por: Zyla, Katarzyna, et al.
Publicado: (2019)

Dimethyl fumarate transfer into human milk
por: Ciplea, Andrea I., et al.
Publicado: (2020)

Drug-Repurposing Strategy for Dimethyl Fumarate
por: Giunta, Salvatore, et al.
Publicado: (2023)

A Case of Progressive Multifocal Leukoencephalopathy in a Fumaric Acid-Treated Psoriasis Patient With Severe Lymphopenia Among Other Risk Factors
por: Engel, Sinah, et al.
Publicado: (2021)

Real-World Safety and Effectiveness of Dimethyl Fumarate in Hispanic or Latino Patients with Multiple Sclerosis: 3-Year Results from ESTEEM
por: Chinea, Angel, et al.
Publicado: (2020)

Predicting optimal response to B-cell depletion with rituximab in multiple sclerosis using CXCL13 index, magnetic resonance imaging and clinical measures
por: Alvarez, Enrique, et al.
Publicado: (2015)

Real-World Safety and Effectiveness of Dimethyl Fumarate in Black or African American Patients with Multiple Sclerosis: 3-Year Results from ESTEEM
por: Williams, Mitzi J., et al.
Publicado: (2020)

Efficacy and tolerability of oral versus injectable disease-modifying therapies for multiple sclerosis in clinical practice
por: Longbrake, Erin E, et al.
Publicado: (2016)

Dimethyl fumarate for treating Papillon–Lefèvre syndrome
por: Al-Omair, Abdullah, et al.
Publicado: (2022)

The Challenge of Dimethyl Fumarate Repurposing in Eye Pathologies
por: Manai, Federico, et al.
Publicado: (2022)

Dimethyl Fumarate as Potential Treatment for Alzheimer’s Disease: Rationale and Clinical Trial Design
por: Sharkus, Robert, et al.
Publicado: (2023)

Effectiveness and safety of dimethyl fumarate in progressive multiple sclerosis
por: Moreira Ferreira, Vanessa F, et al.
Publicado: (2021)

Dimethyl fumarate reduces the risk of mycotoxins via improving intestinal barrier and microbiota
por: Ma, Ning, et al.
Publicado: (2017)

Pharmacokinetics and Bioavailability of Monomethyl Fumarate Following a Single Oral Dose of Bafiertam™ (Monomethyl Fumarate) or Tecfidera(®) (Dimethyl Fumarate)
por: Lategan, Thomas W., et al.
Publicado: (2021)

Dimethyl Fumarate and Its Esters: A Drug with Broad Clinical Utility?
por: Kourakis, Stephanie, et al.
Publicado: (2020)

The Dimethyl Fumarate Experience: A Handy Drug With Broad Clinical Utility
por: Lorefice, Lorena, et al.
Publicado: (2021)

Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centers
por: Vollmer, Brandi, et al.
Publicado: (2018)

Dimethyl fumarate (DMF) vs. monoethyl fumarate (MEF) salts for the treatment of plaque psoriasis: a review of clinical data
por: Landeck, Lilla, et al.
Publicado: (2018)

Safety and efficacy of dimethyl fumarate in ALS: randomised controlled study
por: Vucic, Steve, et al.
Publicado: (2021)

Dimethyl Fumarate Induces Metabolic Crisie to Suppress Pancreatic Carcinoma
por: Chen, Kaiyuan, et al.
Publicado: (2021)

Dimethyl Fumarate and Monoethyl Fumarate Exhibit Differential Effects on KEAP1, NRF2 Activation, and Glutathione Depletion In Vitro
por: Brennan, Melanie S., et al.
Publicado: (2015)

Dimethyl Fumarate Therapy Significantly Improves the Responsiveness of T Cells in Multiple Sclerosis Patients for Immunoregulation by Regulatory T Cells
por: Schlöder, Janine, et al.
Publicado: (2017)

Lymphopenia, Lymphopenia-Induced Proliferation, and Autoimmunity
por: Sheu, Ting-Ting, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_c2r8g37osuk5q3cosrfmh6rrth